IMUGENE CHART. TA only, page-23442

No wonder hot to trot yesterday
ac

SYDNEY, Australia, 1 June 2023: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced the first patient dosed in the combination cohort of the IMPRINTER study, a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx, a B-cell activating immunotherapy alone or in combination with atezolizumab (Tecentriq®), an immune checkpoint inhibitor targeting PD-L1 from Roche, in patients with non-small cell lung cancer (NSCLC). The objectives of the open label, multi-center, dose escalation/expansion, phase 1/1b study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in adults with non-small cell lung cancer (IMPRINTER), are to determine safety, efficacy, and optimal dose of PD1-Vaxx in combination with atezolizumab as therapy in ICI treatment-naïve NSCLC patients or ICI pretreated patients. The study will be conducted at sites in USA and Australia. Dual targeting of the PD-1/PD-L1 axis is an area of considerable interest, providing treatment options for patients with cancer. Combination with PD1-Vaxx may overcome treatment resistance to ICIs with dual inhibition of the PD-1/PD-L1 axis extending the treatment benefit of atezolizumab. In contrast to the combination of two monoclonal antibodies, PD1-Vaxx induces a unique polyclonal immune response which may increase response rates for the combination therapy. Tecentriq® has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the US. In addition to becoming the first approved cancer immunotherapy for adjuvant NSCLC, Tecentriq® was also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide (chemotherapy). Tecentriq® also has four approved indications in advanced NSCLC as either a single agent or in combination with targeted therapies and/or chemotherapies. Imugene MD & CEO Leslie Chong said “It’s an outstanding accomplishment to see Imugene collaborate with Roche, in combination with our PD1-Vaxx drug. PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with NSCLC, and with the first patient being dosed today, we are looking forward to evaluating PD1-Vaxx with atezolizumab in ICI treatment- naïve and pre-treated NSCLC patients.”